安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率

格隆汇
Sep 09
安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药,在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案,与单独使用Imfinzi治疗标准诱导治疗后病情未进展的患者相比的疗效。除总生存期外,该联合疗法还提高了无进展生存期和缓解率。未发现新的安全性问题。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10